Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Common Equity (2022 - 2025)

Praxis Precision Medicines has reported Common Equity over the past 4 years, most recently at $878.1 million for Q4 2025.

  • Quarterly results put Common Equity at $878.1 million for Q4 2025, up 97.13% from a year ago — trailing twelve months through Dec 2025 was $878.1 million (up 97.13% YoY), and the annual figure for FY2025 was $878.1 million, up 97.13%.
  • Common Equity for Q4 2025 was $878.1 million at Praxis Precision Medicines, up from $343.5 million in the prior quarter.
  • Over the last five years, Common Equity for PRAX hit a ceiling of $878.1 million in Q4 2025 and a floor of $64.5 million in Q1 2023.
  • Median Common Equity over the past 4 years was $210.4 million (2022), compared with a mean of $273.7 million.
  • Biggest five-year swings in Common Equity: plummeted 66.25% in 2023 and later skyrocketed 539.38% in 2024.
  • Praxis Precision Medicines' Common Equity stood at $76.1 million in 2022, then dropped by 8.46% to $69.7 million in 2023, then skyrocketed by 539.38% to $445.4 million in 2024, then soared by 97.13% to $878.1 million in 2025.
  • The last three reported values for Common Equity were $878.1 million (Q4 2025), $343.5 million (Q3 2025), and $404.2 million (Q2 2025) per Business Quant data.